SELLAS Life Sciences Group, Inc. SLS

Key data

The business

SELLAS is a clinical-stage cancer company with no approved product and no meaningful sales. Everything rides on acute myeloid leukemia, a fast blood cancer where most patients relapse. The lead asset, galinpepimut-S (GPS), is a peptide immunotherapy meant to train the immune system against WT1, a protein that leukemia cells carry in abundance; it is being tested as maintenance after a patient reaches a second remission. The second asset, SLS009, is a pill that blocks CDK9, an enzyme leukemia cells lean on, tested in newly diagnosed patients alongside standard therapy. The mechanism for both is standard in the WT1 and CDK9 literature, but no primary paper or trial-registry entry was pulled this run, so treat the science as company-described. There is no moat here yet: the moat is a clinical result competitors cannot copy, and SELLAS does not have one until a trial reads out positive.

The numbers

There is no revenue line to read, so the sequence that matters is loss against cash. The last five quarters show the whole story: losses widening while the bank balance multiplied.

Cash rose more than fivefold across a year in which the company lost money every quarter. That gap did not come from operations; it came from selling stock. The quarterly loss is climbing, driven by professional fees and non-cash stock compensation, and each recent quarter landed within a cent of the single analyst estimate, so there is no earnings surprise to trade, only trial news.

The five-year view shows the per-share loss shrinking even as the dollar loss stays heavy, because the share base exploded underneath it.

Here is the compounding math that decides the setup. Weighted-average shares went from about 98.6 million a year ago to 189.2 million last quarter, close to double. That dilution is why the per-share loss looks better while the company still burns tens of millions. The good news buried in it: that cash pile funds roughly four years at last year's pace, which carries SELLAS comfortably past the SLS009 readout due this quarter and likely past the GPS final analysis. A clinical biotech that does not have to raise money into its own catalysts is rare, and it removes the usual death-spiral risk. What the market is not pricing is that neither drug has cleared its bar: the GPS Phase 3 interim at 60 deaths produced only a recommendation to continue, not an early win, and the whole $2.6 billion rests on readouts that have not happened. The single print that settles it is the SLS009 topline in Q4 2026.

Management

The record is mixed in a defensible way. Insiders bought once in the last year, a $100,806 open-market purchase by director Katherine Bach Kalin in November 2025, and sold nothing, so no one cashed out into the ten-bagger. Against that, management issued an enormous amount of stock, doubling the share count, to lift cash from $25 million to $138 million as the price climbed. For a company with no product, selling shares into strength to buy four years of runway is the correct move, not a red flag: it locks in the ability to reach the readouts without begging. Pay design and proxy detail are not in this run's data. The one guidance commitment on the table, SLS009 topline in the fourth quarter of 2026, has been reiterated and is now weeks away.

How it fails or surprises you

SLS009 frontline data, Q4 2026 (right tail). The newer drug reports its first real efficacy read in 28 newly diagnosed AML patients this quarter, with enrollment described as ahead of standard. The market credits GPS more than this wholly-owned pill. A response rate clearly above the frontline standard would re-rate the company on a second asset investors are barely paying for. The print: the topline response and remission rates.

REGAL final analysis, at 80 events. The GPS Phase 3 only reports once 80 enrolled patients have died, and the earlier 60-event interim earned a continuation, not an efficacy stop. If the overall-survival result misses at the final analysis, GPS is worth little and most of the $2.6 billion has no support. The number: the survival hazard ratio at 80 events.

The valuation itself. A $2.6 billion cap on zero revenue after a roughly 10x run in a year is the fact this read explains least. Nothing fundamental was de-risked; positioning moved. If momentum reverses before a catalyst lands, or the next raise prices lower, the stock behaves as pure sentiment. What proves the bullish read wrong is the price falling on no news.

Closing thoughts

A single readout settles most of this, and it arrives soon. Between now and year-end the SLS009 topline converts the newer program from hope into a number, and further out the REGAL 80-event analysis decides GPS outright. The downside tail is the fatter one: the cap already prices success, and the Phase 3 interim gave only a lukewarm continuation, so a miss on either readout takes out most of the equity value. The offsetting fact, and it is a real one, is that the cash removes financing risk entirely through both events, so the company will not be forced to sell the story cheap to survive. What is at risk if REGAL misses is the bulk of the $2.6 billion; what SLS009 is worth if it lands is a second shot the market is treating as a free option.

The bet is still that one of SELLAS's two cancer drugs works in AML trials and wins FDA approval. It breaks if the REGAL final analysis misses on overall survival, or if the SLS009 topline this quarter disappoints. The one pair of numbers that tells you first is the SLS009 response rate in Q4 2026 and REGAL's death count marching toward 80. Priced for the wins, funded to find out, proven on neither.